All In Biotech

NDA 020766 · Cheplapharm

Xenical

Orlistat · Oral · Intestinal Lipase Inhibitor

NovelPriority review

Last checked: Nov 20, 2026Latest source record: Sep 30, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1999

Apr 23, 1999

Approved uses

3

Original approval plus efficacy supplements

Registered trials

65

3 Phase 3, 1 recruiting

FAERS reports

4,500

4,018 serious, 212 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 30, 2026.

XENICAL is indicated in combination with a reduced calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in: adults and pediatric patients aged 12 years and older with obesity. adults with overweight in the presence of at least one weight-related comorbid condition. XENICAL is an intestinal lipase inhibitor indicated in combination with a reduced calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in: ( 1 ) adults and pediatric patients aged 12 years and older with obesity. adults with overweight in the presence of at least one weight-related comorbid condition.

Mechanism: Orlistat is a reversible inhibitor of gastrointestinal lipases. It exerts its therapeutic activity in the lumen of the stomach and small intestine by forming a covalent bond with the active serine residue site of gastric and pancreatic lipases. The inactivated enzymes are thus unavailable to hydrolyze dietary fat in the form of triglycerides into absorbable free fatty acids and monoglycerides. Undigested triglycerides are not absorbed, resulting in a caloric deficit.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • XENICAL · ORLISTAT 120MG · CAPSULE, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Orlistat" as an intervention, any sponsor and status, largest first.

All 65 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • diarrhoea265
  • drug ineffective231
  • nausea210
  • drug interaction203
  • abdominal pain193
  • headache182
  • vomiting182
  • weight increased177
  • dyspnoea173
  • fatigue171
  • dizziness143
  • pain134

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004235
2005229
2006262
2007490
2008565
2009320
2010209
2011175
2012174
2013147
2014147
2015155
2016134
2017202
2018279
2019142
2020122
202194
202275
202369
202482
2025109
202684

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Xenical (Orlistat)

2024 spending

$182K

Beneficiaries

98

198 claims

Per beneficiary

$1,861

$5.68 per unit

View as table
YearSpending
2020$737,509
2021$702,904
2022$665,880
2023$283,460
2024$182,413

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 428 on PubMed

Sponsor: Cheplapharm

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.